EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals Inc. (NASDAQ: CPEX) today announced that its partner, Serenity Pharmaceuticals, has entered into a global agreement with Allergan, Inc. (NYSE: AGN) for the development and commercialization of Ser-120, a product candidate currently in Phase III clinical trials for the treatment of nocturia that utilizes CPEX’s patented intranasal drug delivery technology. In connection with its agreement with Serenity, Allergan is assuming the exclusive license agreement between CPEX and Serenity that the companies entered into in February 2008.
